Chief Executive Albert Bourla said that 2023 should be a “transition year” for Pfizer’s COVID products, before potentially returning to growth in 2024.
Chief Executive Albert Bourla said that 2023 should be a “transition year” for Pfizer’s COVID products, before potentially returning to growth in 2024.
The company launched five new products last year and hopes to introduce as many as 14 more over the next year and a half, including a vaccine for respiratory syncytial virus and an mRNA flu vaccine. Pfizer has turned to acquisitions such as its $5.4 billion buyout of Global Blood Therapeutics and its $11.6 billion purchase of migraine drugmaker Biohaven to bolster its pipeline of future products.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer tops profit expectations but gives downbeat outlook, as COVID product sales set to tumbleShares of Pfizer Inc. dropped 2.2% toward a 3 1/2-month low in premarket trading Tuesday, after the drug maker reported fourth-quarter profit that topped...
Read more »
Pfizer forecasts steep fall in 2023 sales of COVID productsPfizer Inc on Tuesday forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and pill in 2023, intensifying investor concerns over demand for the products as governments reduce orders.
Read more »
Pfizer and Moderna quadrupling price of COVID vaccine raises concernsLawmakers from both the U.S. and U.K. have written to the two pharmaceutical companies to express concerns over plans to raise the price of a dose to $110-$130.
Read more »
Pfizer’s COVID revenues have dropped off along with attention to the pandemicWall Street urged Pfizer to lower its COVID revenue estimates. The company did — but it's still betting on higher demand for its vaccine and antiviral by 2025.
Read more »
Floki Inu DAO Passes Proposal to Burn Over $100M Worth of TokensOver 99% of the RealFlokiInu community voted to burn 4.2 trillion FLOKI tokens currently worth over $100 million. By shauryamalwa.
Read more »
Cronos Labs to accept second cohort for $100M-backed Web3 accelerator programCronos Labs’ $100M accelerator program is focused on the DeFi, GameFi, SocialFi and infrastructure verticals, and will accept applications until March 24, 2023.
Read more »